Synthesis and Novel Salt Forms of (R)-3-((E)-pyrrolidin-3-yl)vinyl)-5-tetrahydropyran-4-yloxy)pyridine

The present invention relates to (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine, its salt forms, and to processes for the commercial-scale production of these compounds in sufficient purity and quality for use in pharmaceutical compositions. 1. (R)-3-((E)-2-(Pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine mono-L-malate or a hydrate or solvate thereof.2. (canceled)3. (canceled)4. (canceled)5. (R)-3-((E)-2-(Pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine or a pharmaceutically acceptable salt thereof substantially free of (S)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine.6. A pharmaceutical composition comprising a compound according to and one or more pharmaceutically acceptable adjuvant claim 1 , carrier claim 1 , or excipient7. The pharmaceutical composition of further comprising one or more additional therapeutic agent.8. A compound selected from (R)-3-((E)-2-(Pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine mono-L-malate claim 6 , (R)-3-((E)-2-(Pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine hemi-galactarate claim 6 , (R)-3-((E)-2-(Pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine oxalate claim 6 , and (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine di-p-toluoyl-D-tartrate.9. A method for the treatment or prevention of a NNR mediated disorder comprising administering to a mammal in need of such treatment claim 6 , a therapeutically effective amount of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine mono-L-malate.10. (canceled)11. The method of claim 9 , wherein the disorder is selected from the group consisting of CNS disorders claim 9 , inflammation claim 9 , inflammatory response associated with bacterial and/or viral infection claim 9 , pain claim 9 , metabolic syndrome claim 9 , autoimmune disorders.12. The method of claim 11 , wherein the CNS disorder is selected from cognitive dysfunction in schizophrenia (CDS ...

FUSED BENZOAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS

The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS). 2. (canceled)3. The compound of claim 1 , wherein the compound is a tautomer.45-. (canceled)6. The compound of claim 1 , wherein Xis N.7. (canceled)8. The compound of claim 1 , wherein Ris H.9. The compound of claim 1 , wherein Ris Calkyl.10. The compound of claim 1 , wherein the compound is selected from:7,8,9,10-tetrahydro-6H-azepino[4,5-g]quinoxaline; 8-methyl-7,8,9,10-tetrahydro-6H-azepino[4,5-g]quinoxaline; 2-methyl-7,8,9,10-tetrahydro-6H-azepino[4,5-g]quinoxaline; 2,3-dimethyl-7,8,9,10-tetrahydro-6H-azepino[4,5-g]quinoxaline; 2-methyl-3-ethyl-7,8,9,10-tetrahydro-6H-azepino[4,5-g]quinoxaline; 2,3-diethyl-7,8,9,10-tetrahydro-6H-azepino[4,5-g]quinoxaline; 2,8-dimethyl-7,8,9,10-tetrahydro-6H-azepino[4,5-g]quinoxaline; 7,8,9,10-tetrahydro-6H-azepino[4,5-g]quinoxalin-2(1H)-one; 2-chloro-7,8,9,10-tetrahydro-6H-azepino[4,5-g]quinoxaline; 2-chloro-8-methyl-7,8,9,10-tetrahydro-6H-azepino[4,5-g]quinoxaline; 2-methoxy-7,8,9,10-tetrahydro-6H-azepino[4,5-g]quinoxaline; 2-methoxy-8-methyl-7,8,9,10-tetrahydro-6H-azepino[4,5-g]quinoxaline; 2-(N-methylamino)-7,8,9,10-tetrahydro-6H-azepino[4,5-g]quinoxaline; 2-(N,N-dimethylamino)-7,8,9,10-tetrahydro-6H-azepino[4,5-g]quinoxaline; 2-(N-benzylamino)-7,8,9,10-tetrahydro-6H-azepino[4,5-g]quinoxaline; 2-(3-pyridinyl)-7,8,9,10-tetrahydro-6H-azepino[4,5-g]quinoxaline; 7,8,9,10-tetrahydro-6H-azepino[4,5-g]quinoline; 8-methyl-7,8,9,10-tetrahydro-6H-azepino[4,5-g]quinoline; 2-methyl-7,8,9,10-tetrahydro-6H-azepino[4,5-g]quinoline; 2,3-dimethyl-7,8,9,10-tetrahydro-6H-azepino[4,5-g]quinoline; 2,8-dimethyl-7,8,9,10-tetrahydro-6H-azepino[4,5- ...

Combination therapy for the management of hypertension

The present invention includes a combination comprising: a) mecamylamine; and b) an ACE inhibitor, an AT2 receptor inhibitor, a renin inhibitor, or a combination thereof.

(2S,3R)-N-(2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)BENZOFURN-2-CARBOXAMIDE, NOVEL SALT FORMS, AND METHODS OF USE THEREOF

The present invention relates to (2S,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms thereof, methods for its preparation, novel intermediates, and methods for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central and autonomic nervous systems. 1. A compound (2S ,3R)N-(2-((3-pyridinyl)methyl-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide or a pharmaceutically acceptable salt thereof , substantially free of (2S ,3S)N-(2-((3-pyridinyl)methyl-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide or a pharmaceutically acceptable salt thereof , (2R ,3S)N-(2-((3-pyridinyl)methyl-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide or a pharmaceutically acceptable salt thereof , or (2R ,3R)N-(2-((3-pyridinyl)methyl-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide or a pharmaceutically acceptable salt thereof.2. A method for treating or preventing a central nervous system disorder claim 1 , inflammation claim 1 , pain claim 1 , or neovascularization comprising administering the compound of .3. The method of claim 2 , wherein the central nervous system disorder is selected from mild cognitive impairment claim 2 , age-associated memory impairment claim 2 , pre-senile dementia claim 2 , early onset Alzheimer's disease claim 2 , senile dementia claim 2 , dementia of the Alzheimer's type claim 2 , Alzheimer's disease claim 2 , Lewy Body dementia claim 2 , micro-infarct dementia claim 2 , AIDS-related dementia claim 2 , HIV-dementia claim 2 , multiple cerebral infarcts claim 2 , Parkinsonism claim 2 , Parkinson's disease claim 2 , Pick's disease claim 2 , progressive supranuclear palsy claim 2 , Huntington's chorea claim 2 , tardive dyskinesia claim 2 , hyperkinesia claim 2 , mania claim 2 , attention deficit disorder claim 2 , attention deficit hyperactivity disorder claim 2 , anxiety claim 2 , depression claim 2 , dyslexia claim 2 , schizophrenia claim 2 , ...

3-Substituted-2-(arlyalkyl)-1-azabicycloalkanes and Methods of Use Thereof

The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is typically a Calkyl. The substituent at the 3-position of the 1-azabicycloalkane is a carbonyl group-containing moiety, such as an amide, carbamate, urea, thioamide, thiocarbamate, thiourea or similar functionality. The compounds exhibit activity at nicotinic acetylcholine receptors (nAChRs), particularly the α7 nAChR subtype, and are useful towards modulating neurotransmission and the release of ligands involved in neurotransmission. Methods for preventing or treating conditions and disorders, including central nervous system (CNS) disorders, which are characterized by an alteration in normal neurotransmission, are also disclosed. Also disclosed are methods for treating inflammation, autoimmune disorders, pain and excess neovascularization, such as that associated with tumor growth. 1. A method of ameliorating one or more symptoms associated with Parkinsonism comprising administering to a subject in need thereof a therapeutically effective amount of (R ,R;R ,S;S ,R; and S ,S)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide or a pharmaceutically acceptable salt thereof , wherein the administration of (R ,R;R ,S;S ,R; and S ,S)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide or a pharmaceutically acceptable salt thereof , improves cognition.2. A method for treating one or more of Parkinsonism , Parkinson's Disease , cognitive deficits in Parkinson's Disease , and dyskinesias comprising administering to a subject in need thereof a therapeutically effective amount of (R ,R;R ,S;S ,R; and S ,S)—N-(2 ...

Reversal of l-dopa-induced dyskinesia by neuronal nicotinic receptor ligands

The present invention includes methods, uses, and compounds for treating or preventing L-dopa-induced dyskinesias.

Exo-s-mecamylamine method, use, and compound for treatment

The present invention relates to exo-S-mecamylamine and the use of exo-S-mecamylamine in medical treatments.

POPPET VALVE ASSEMBLY FOR CONTROLLING A PNEUMATIC ACTUATOR

A poppet valve assembly to control a pneumatic actuator may include a housing having a central bore. A first module may be disposed within the central bore, and the first module may have a first and second poppet valve. A second module may also be disposed within the central bore, and the second module may have a third and fourth poppet valve. A supply of pressurized fluid may be in fluid communication with a plurality of control valves such that pressurized fluid from the control valves opens and closes the poppet valves. The supply of pressurized fluid may also be in fluid communication with the first module and the second module such that the opening and closing of the poppet valves controls the position of the pneumatic actuator. 1. A poppet valve assembly comprising:a valve housing having a central bore;a first module disposed within the central bore, the first module comprising a first normally closed poppet valve and a second normally closed poppet valve, wherein each of the first and second normally closed poppet valves has an open position and a closed position;a central port formed in the first module, wherein the central port of the first module is adapted to be coupled to a first volume of a pneumatic cylinder;an exhaust port formed in the first module such that the central port is in fluid communication with the exhaust port when the first poppet valve is in the open position; anda supply port formed in the first module such that the central port is in fluid communication with the supply port when second poppet valve is in the open position,wherein the supply port is configured to be in fluid communication with a supply of pressurized fluid such that when the second poppet valve is in the open position, pressurized fluid is provided to the first volume of the pneumatic cylinder, andwherein the exhaust port is configured to vent pressurized fluid from the first volume of the pneumatic cylinder when the first poppet valve is in the open position.2. The ...

Nicotinic Acetylcholine Receptor Sub-Type Selective Amides of Diazabicycloalkanes

Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are amide compounds which can be prepared from certain heteroaryl carboxylic acids and certain diazabicycloalkanes. The compounds exhibit selectivity for, and bind with high affinity to, neuronal nicotinic receptors of the α4β2 subtype in the central nervous system (CNS). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly CNS disorders. The compounds can: (i) alter the number of nicotinic cholinergic receptors of the brain of the patient, (ii) exhibit neuroprotective effects, and (iii) when employed in effective amounts, not result in appreciable adverse side effects (e.g. side effects such as significant increases in blood pressure and heart rate, significant negative effects upon the gastrointestinal tract, and significant effects upon skeletal muscle).

3,6-Diazabicyclo[3.1.1]heptanes as Neuronal Nicotinic Acetycholine Receptor Ligands

The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS). 3. The compound of or , where m is 0.4. The compound of or , where m is 1.5. A compound selected from:3-methylcarbonyl-3,6-diazabicyclo[3.1.1]heptane;3-isopropylcarbonyl-3,6-diazabicyclo[3.1.1]heptane;3-cyclopropylcarbonyl-3,6-diazabicyclo[3.1.1]heptane;3-propoxycarbonyl-3,6-diazabicyclo[3.1.1]heptane;3-isopropoxycarbonyl-3,6-diazabicyclo[3.1.1]heptanes;3-methoxyethoxycarbonyl-3,6-diazabicyclo[3.1.1]heptane;3-(2-fluoroethoxy)carbonyl-3,6-diazabicyclo[3.1.1]heptane;3-(2-bromofuran-5-yl)carbonyl-3,6-diazabicyclo[3.1.1]heptane;3-(3-bromofuran-5-yl)carbonyl-3,6-diazabicyclo[3.1.1]heptane;3-(3-chlorofuran-2-yl)carbonyl-3,6-diazabicyclo[3.1.1]heptane;3-(isoxazol-5-yl)carbonyl-3,6-diazabicyclo[3.1.1]heptane;3-(2-methoxyethyl)carbonyl-3,6-diazabicyclo[3.1.1]heptane;3-(2,2,2-trifluoroethyl)carbonyl-3,6-diazabicyclo[3.1.1]heptane;3-(tetrahydrofuran-3-yl)carbonyl-3,6-diazabicyclo[3.1.1]heptane;6-(2-chlorofuran-5-yl)carbonyl-3,6-diazabicyclo[3.1.1]heptane;6-(2-bromorofuran-5-yl)carbonyl-3,6-diazabicyclo[3.1.1]heptane;6-cyclobutylcarbonyl-3,6-diazabicyclo[3.1.1]heptane;6-(2-methoxyethyl)carbonyl-3,6-diazabicyclo[3.1.1]heptane;cis-3-(2-fluorocycloprop-1-yl)carbonyl-3,6-diazabicyclo[3.1.1]heptane;trans-3-(2-fluorocycloprop-1-yl)carbonyl-3,6-diazabicyclo[3.1.1]heptane;cis-6-(2-fluorocycloprop-1-yl)carbonyl-3,6-diazabicyclo[3.1.1]heptane; andtrans-6-(2-fluorocycloprop-1-yl)carbonyl-3,6-diazabicyclo[3.1.1]heptane;or a pharmaceutically acceptable salt thereof.6. A compound 3-cyclopropylcarbonyl-3 ,6-diazabicyclo[3.1.1]heptane or a pharmaceutically acceptable salt thereof.7. A ...

VALVE SIGNATURE DIAGNOSIS AND LEAK TEST DEVICE

A valve signature diagnosis and leak testing device includes a spool valve operatively connected to a pilot valve, the pilot valve being configured to position the spool valve to one of an open position and a closed position. A blocker valve is fluidly connected to a control fluid outlet of the spool valve. An electrical module is operatively connected to the pilot valve, a supply of control fluid, and the blocker valve, the electrical module being capable of sending pulsed electrical signals to the pilot valve and the blocker valve to selectively position the spool valve and the blocker valve to an open or closed position. 1. A valve signature diagnosis and leak testing device for a control valve , the valve signature diagnosis and leak testing device comprising:a spool valve operatively connected to a pilot valve, the pilot valve being configured to position the spool valve to one of an open position and a closed position, the spool valve including a first control fluid inlet, a first control fluid outlet, and a second control fluid outlet, the first control fluid inlet being fluidly connected to a supply of control fluid and the first control fluid outlet being configured to be connected to a valve actuator;a blocker valve fluidly connected to the second control fluid outlet; andan electrical module operatively connected to the pilot valve, the supply of control fluid, and the blocker valve, the electrical module being capable of sending pulsed electrical signals to the pilot valve and the blocker valve to selectively position the spool valve and the blocker valve to an open or a closed position,wherein the open position of the spool valve fluidly connects the first control fluid inlet to the first control fluid outlet and the closed position of the spool valve fluidly connects the first control fluid outlet to the second control fluid outlet.2. The valve signature diagnosis and leak testing device of claim 1 , wherein the electrical module includes a main ...

Nicotinic Acetylcholine Receptor Sub-Type Selective Amides of Diazabicycloalkanes

Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are amide compounds which can be prepared from certain heteroaryl carboxylic acids and certain diazabicycloalkanes. The compounds exhibit selectivity for, and bind with high affinity to, neuronal nicotinic receptors of the α4β2 subtype in the central nervous system (CNS). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly CNS disorders. The compounds can: (i) alter the number of nicotinic cholinergic receptors of the brain of the patient, (ii) exhibit neuroprotective effects, and (iii) when employed in effective amounts, not result in appreciable adverse side effects (e.g. side effects such as significant increases in blood pressure and heart rate, significant negative effects upon the gastrointestinal tract, and significant effects upon skeletal muscle). 115-. (canceled)16. A method for treating age-associated memory impairment , mild cognitive impairment , pre-senile dementia , early onset Alzheimer's disease , senile dementia , dementia of the Alzheimer's type , Lewy body dementia , vascular dementia , Alzheimer's disease , stroke , AIDS dementia complex , attention deficit hyperactivity disorder , dyslexia , schizophrenia , schizophreniform disorder , cognitive deficits of schizophrenia , or schizoaffective disorder comprising administering N-(5-chlorofuran-2-ylcarbonyl)-3 ,7-diazabicyclo[3.3.0]octane , or a pharmaceutically acceptable salt thereof.17. A method for treating mild to moderate dementia of the Alzheimer's type , mild cognitive impairment , or age associated memory impairment comprising administering N-(5-chlorofuran-2-ylcarbonyl)-3 ,7-diazabicyclo[3.3.0]octane , or a pharmaceutically acceptable salt thereof.18. A method for treating attention deficit disorder or attention deficit hyperactivity disorder comprising administering N-(5-chlorofuran-2 ...

WIRELESS MONITORING AND CONTROL OF SAFETY STATIONS IN A PROCESS PLANT

A safety station for use in a process plant includes one or more leverless limit switches to detect activation of one or more parts of the safety station. The safety station further includes a wireless transmitter coupled to the leverless limit switches to transmit signals associated with the safety station to a base station device, which is communicatively coupled to one or more control and/or monitoring devices. 1. A safety station for use in a process plant , the safety station comprising:one or more leverless limit switches to detect activation of one or more parts of the safety station; anda wireless transmitter coupled to the leverless limit switches to transmit signals associated with the safety station to a base station device, wherein the base station device is communicatively coupled to one or more control and/or monitoring modules.2. The safety station of claim 1 , wherein the leverless limit switch is a GO® switch manufactured by the TopWorx corporation.3. The safety station of claim 1 , wherein the leverless limit switch remains latched until physically reset.4702. The safety station of claim 1 , wherein the wireless transmitter is the Rosemount dual input transmitter manufactured by the Emerson corporation.5. The safety station of claim 1 , wherein the wireless transmitter is an intrinsically safe wireless transmitter.6. The safety station of claim 1 , wherein the safety station is a safety shower and/or an eye wash station.7. The safety station of claim 1 , wherein at least one of the one or more control and/or monitoring stations is a remote touch screen panel.8. The safety station of claim 1 , wherein at least one of the one or more control and/or monitoring stations is a paperless recorder.9. The safety station of claim 1 , wherein at least one of the one or more control and/or monitoring stations is a workstation.10. A safety station monitoring and control system in a process plant claim 1 , the system comprising:one or more safety stations ...

SWITCH MODULE

A switch module used for position sensing may be operated in a number of modes for compatibility with a number of legacy position sensing products. A dry switch circuit can be configured to provide a direct output, emulating dry reed, high-side or low-side switched configurations. Alternatively, the dry switch circuit can be connected to an input of a NAMUR circuit to provide the known current output for that standard. In another configuration the dry switch can be selectively coupled to one of two NAMUR circuits allowing the switch module to provide a low-to-high current NAMUR output or a high-to-low current NAMUR output. 1. A switch module arranged and adapted to report a position of a moveable element external to the switch module , the switch module comprising:a first external connection, a second external connection, and a third external connection;a dry contact relay having a relay contact position responsive to a position of a component external to the switch module, the dry contact relay having a common connection, a normally open connection and a normally closed connection, where the normally open connection corresponds to a first position of the moveable element and the normally closed connection corresponding to a second position of the moveable;a NAMUR circuit having a first input connection pair and a first output connection pair;an electrical connection from the normally open connection of the dry relay to a first input of the first input connection pair of the NAMUR circuit;a selector operable to connect the common connection of the dry contact relay to i) a null contact of the selector or ii) a second input of the first input connection pair of the NAMUR circuit;a second electrical connection from the first output of the NAMUR circuit to one of the first external connection or the second external connection; anda third electrical connection between the second output of the NAMUR circuit to the third external connection;a first jumper that removeably ...

ARYLVINYLAZACYCLOALKANE COMPOUNDS FOR CONSTIPATION

The present invention relates to method of treating constipation and enhancing colonic motility by administration of 5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine or a pharmaceutically acceptable salt thereof. 1. A method for relieving constipation comprising administration of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine or a pharmaceutically acceptable salt thereof.2. The method of claim 1 , wherein the constipation is gastrointestinal claim 1 , endrocrinological claim 1 , neurological claim 1 , iatrogenic claim 1 , associated with an eating disorder claim 1 , or related to an injury.3. A method for treating constipation associated with a gastrointestinal disorder comprising administration of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine or a pharmaceutically acceptable salt thereof.4. The method of claim 3 , wherein the gastrointestinal disorder is irritable bowel syndrome claim 3 , constipation predominant irritable bowel syndrome claim 3 , alternating irritable bowel syndrome claim 3 , chronic idiopathic constipation claim 3 , acute constipation claim 3 , drug-induced constipation claim 3 , colonic disorders claim 3 , colon cancer claim 3 , or ileus paralyticus.5. The method of claim 4 , wherein the drug-induced constipation is opioid-induced constipation claim 4 , antidepressant-induced constipation claim 4 , antacid-induced constipation claim 4 , or iron supplement-induced constipation.6. A method for treating constipation from an endocrinological source comprising administration of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine or a pharmaceutically acceptable salt thereof.7. The method of claim 6 , wherein the endocrinological source is pregnancy or hypothyroidism.8. A method for treating constipation associated with a neurological condition comprising administration of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine or a pharmaceutically acceptable salt thereof.9. The method of claim 8 , wherein the neurological condition is Parkinson's Disease claim 8 , multiple ...

METHOD OF TREATING BLADDER DISORDERS

The present invention relates to dexmecamylamine and the use of dexmecamylamine, substantially free of exo-R-mecamylamine, in the treatment of bladder disorders, including overactive bladder. 1. A method of treating overactive bladder , the method comprising the administration of a therapeutically effective amount of dexmecamylamine or a pharmaceutically acceptable salt thereof , substantially free of exo-R-mecamylamine , to a subject with overactive bladder.2. The method according to claim 1 , wherein the administration of dexmecamylamine is sufficient to increase the micturition interval relative to baseline in the subject in need thereof.3. The method according to claim 1 , wherein the administration of dexmecamylamine is sufficient to increase the micturition interval by at least 10% relative to baseline in the subject in need thereof.4. The method according to claim 1 , wherein the administration of dexmecamylamine is sufficient to increase the micturition interval by at least 10% relative to baseline without significant detrimental changes in bladder contraction amplitude in the subject in need thereof.5. A method of treating overactive bladder claim 1 , the method comprising the oral administration of dexmecamylamine or a pharmaceutically acceptable salt thereof in an amount from about 0.1 mg to about 2.0 mg BID claim 1 , substantially free of exo-R-mecamylamine claim 1 , to a subject with overactive bladder.6. The method according to claim 5 , wherein the oral administration of dexmecamylamine is sufficient to increase the micturition interval by at least 10% relative to baseline in the subject in need thereof.7. The method according to claim 5 , wherein the dexmecamylamine or a pharmaceutically acceptable salt thereof is orally administered in an amount of about 0.5 mg BID.8. The method according to claim 5 , wherein the dexmecamylamine or a pharmaceutically acceptable salt thereof is orally administered in an amount of about 1.0 mg BID.9. The method ...

CHEMICAL ENTITY SEARCH, FOR A COLLABORATION AND CONTENT MANAGEMENT SYSTEM

A method of obtaining chemical or molecular compound information from a document is provided. The method includes applying optical structure recognition to a document and extracting compound structure information from data obtained by applying the optical structure recognition. The method includes applying a text search module to a main body of the document and metadata of the document and extracting one or more chemical names from data obtained by applying the text search module to the main body and to the metadata. The method includes storing, in a database, an identifier, the compound structure information, and the one or more chemical names, wherein at least one method operation is executed through a processor. 1. A method of managing a database relating to chemical or molecular compounds , the method comprising:extracting at least one first chemical name from the document in response to at least a portion of the document having a type of text format;extracting compound structure information via optical structure recognition applied to the document in response to the document having at least one image;extracting at least one second chemical name via optical character recognition applied to the document in response to the document having text that is susceptible to optical character recognition;extracting at least one third chemical name from metadata of the document in response to the document having metadata;extracting molecular string information from the document in response to the document having molecular string information; andstoring in a database, under an identifier associated with the document, the compound structure information, the at least one first chemical name, the at least one second chemical name, the at least one third chemical name, the molecular string information and the compound structure information.2. The method of claim 1 , further comprising:storing in the database, under the identifier, a title of the document and location information ...

NOVEL POLYMORPH FORMS OF (2S)-(4E)-N-METHYL-5-[3-(5-ISOPROPOXYPYRIDIN)YL]-4-PENTEN-2-AMINE

Polymorph forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine p-hydroxybenzoate, and methods for their preparation, pharmaceutical composition containing said polymorph(s) and use, are disclosed. The polymorphs can be administered to patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, to treat and/or prevent such disorders. 1. A method for treatment of a central nervous system disorder , comprising administering to a mammal , in need of such treatment , a therapeutically effective amount of:a crystalline polymorph B of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine p-hydroxybenzoate, exhibiting an X-ray powder diffraction pattern having characteristic peaks expressed in degrees (2-0°) at around 8.0, 9.,6 and 16.1; ora mixture of polymorphs comprising polymorph A of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine p-hydroxybenzoate, exhibiting an X-ray powder diffraction pattern having characteristic peaks expressed in degrees (2-0°) at around 7.6, 15.2, and 19.7; and polymorph B of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine p-hydroxybenzoate, exhibiting an X-ray powder diffraction pattern having characteristic peaks expressed in degrees (2-0°) at around 8.0, 9.6, and 16.1, in ratios of 5:95 to 95:5.2. The method of claim 1 , wherein the disorder is selected from the group consisting of age-associated memory impairment claim 1 , mild cognitive impairment claim 1 , presenile dementia claim 1 , early onset Alzheimer's disease claim 1 , senile dementia claim 1 , dementia of the Alzheimer's type claim 1 , Lewy body dementia claim 1 , vascular dementia claim 1 , Alzheimer's disease claim 1 , stroke claim 1 , AIDS dementia complex claim 1 , attention deficit disorder claim 1 , attention deficit hyperactivity disorder claim 1 , dyslexia claim 1 , schizophrenia claim 1 , schizophreniform disorder claim 1 , and schizoaffective disorder.3. ...

TREATMENT OF COGNITIVE DYSFUNCTION IN SCHIZOPHRENIA

The present invention relates to (2S,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide or a pharmaceutically acceptable salt thereof, pharmaceutical compositions, and methods for treating schizophrenia. 1. A method for the treatment of cognitive dysfunction in schizophrenia comprising administering (2S ,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide or a pharmaceutically acceptable salt thereof to a patient in need thereof.2. (canceled)3. (canceled)4. The method of claim 1 , wherein the treatment provides an improvement in executive function.5. The method of claim 1 , wherein the treatment provides an improvement in memory.6. The method of claim 1 , wherein the treatment provides an improvement in attention.7. A method for the treatment of negative symptoms of schizophrenia comprising administering (2S claim 1 ,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide or a pharmaceutically acceptable salt thereof to a patient in need thereof.8. (canceled)9. (canceled)10. A method for the treatment of residual phase schizophrenia comprising administering (2S claim 1 ,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide or a pharmaceutically acceptable salt thereof to a patient in need thereof.11. (canceled)12. (canceled)13. A pharmaceutical composition for the treatment of one or more of cognitive dysfunction in schizophrenia claim 1 , negative symptoms of schizophrenia claim 1 , or residual phase schizophrenia comprising (2S claim 1 ,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.14. The pharmaceutical composition of claim 13 , wherein the composition further comprises one or more antipsychotic medications claim 13 , anti-depressants claim 13 , or mood stabilizers.15. The pharmaceutical composition of ...

(2S,3R)-N-(2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)BENZYOFURN-2-CARBOXAMIDE, NOVEL SALT FORMS, AND METHODS OF USE THEREOF

The present invention relates to (2S,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms thereof, methods for its preparation, novel intermediates, and methods for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central and autonomic nervous systems. 1. A method for treating one or more of mild cognitive impairment , age-associated memory impairment , pre-senile dementia , early onset Alzheimer's disease , senile dementia , dementia of the Alzheimer's type , or Alzheimer's disease comprising administering a compound (2S ,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide or a pharmaceutically acceptable salt thereof , substantially free of (2S ,3S)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide , (2R ,3S)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide , (2R ,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide , and pharmaceutically acceptable salts thereof.2. The method of claim 1 , wherein the treatment is for Alzheimer's disease.3. The method of claim 1 , wherein the treatment is for early onset Alzheimer's disease. The present invention is a continuation of U.S. patent application Ser. No. 13/116,080, filed May 26, 2011, which is a continuation of U.S. patent application Ser. No. 12/184,312, filed Aug. 1, 2008, now U.S. Pat. No. 7,981,906 issued Jul. 19, 2011, which claims benefit to U.S. Provisional Application Nos. 60/971,654, filed Sep. 12, 2007, 60/953,610, filed Aug. 2, 2007, 60/953,613, filed Aug. 2, 2007, and 60/953,614 filed Aug. 2, 2007, each of which is incorporated herein by reference in its entirety.The present invention relates to (2S,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms thereof, methods for its preparation, novel intermediates, and methods for treating ...

HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS

Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof compositions that are hydroxybenzoate salts of E-metanicotine-type compounds. The formation of hydroxybenzoate salts of the E-metanicotine compounds is also useful in purifying the E-metanicotine compounds, as the hydroxybenzoate salts tend to crystallize out, leaving impurities such as Z-metanicotine compounds, and compounds where the double bond has migrated, in solution. If desired, the hydroxybenzoate salts can be converted to either the free base (the E-metanicotine) or to another pharmaceutically acceptable salt form. 1. A method for treating a CNS disorder comprising administering to a subject in need thereof an effective amount of a composition comprising (2S)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridinyl)-4-penten-2-amine p-hydroxybenzoate , optionally along with a pharmaceutically acceptable carrier.2. A method for treating Alzheimer's disease comprising administering to a subject in need thereof an effective amount the composition according to .3. A method for treating early onset Alzheimer's disease comprising administering to a subject in need thereof an effective amount the composition according to .4. A method for treating dementia comprising administering to a subject in need thereof an effective amount the composition according to .5. A method for treating a cognitive disorder comprising administering to a subject in need thereof an effective amount the composition according to . This application is a divisional of U.S. patent application Ser. No. 13/281,716, filed Oct. 26, 2011, now allowed, which is a continuation of U.S. patent application Ser. No. 12/264,288, filed Nov. 4, 2008, now U.S. Pat. No. 8,053,451, issued Nov. 8, 2011, which is a continuation of Ser. No. 11/270,018 filed Nov. 9, 2005, now U.S. Pat. No. 7,459,469, issued Dec. 2, 2008, which claims benefit of U.S. Provisional ...

Synthesis and novel salt forms of (r)-5-((e)-2-pyrrolidin-3ylvinyl)pyrimidine

The present invention relates to the stereospecific synthesis of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, its salt forms, and novel polymorphic forms of these salts.

ARYLVINYLAZACYCLOALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF

Novel vinylazacycloalkane compounds of Formula (I) are disclosed. The compounds are ligands of various nAChRs. The compounds and their pharmaceutically acceptable salts can be used to prepare pharmaceutical compositions and/or medicaments intended to prevent or treat disorders associated with dysfunction of nAChRs, especially within the central nervous system or the gastrointestinal system. Examples of types of disorders that can be treated include neurodegenerative disorders, including central nervous system disorders such as Alzheimer's disease, cognitive disorders, motor disorders such as Parkinson's disease, drug addiction, behavioral disorders and inflammatory disorders within the gastrointestinal system. The compounds can also serve as analgesics in the treatment of acute, chronic or recurrent pain. 2. The method of claim 1 , wherein the gastrointestinal disorder is Crohn's Disease claim 1 , Irritable Bowel Syndrome claim 1 , or Ulcerative Colitis. The present application is a continuation of U.S. application Ser. No. 13/033,719, filed Feb. 24, 2011, which is a continuation of U.S. application Ser. No. 12/348,605, filed Jan. 5, 2009, which is a divisional of U.S. application Ser. No. 11/206,243, filed Aug. 17, 2005, which is a divisional of U.S. application Ser. No. 10/379,868, filed Mar. 5, 2003, now U.S. Pat. No. 7,098,331, each of which is incorporated herein by reference.The present invention relates to pharmaceutical compositions incorporating compounds capable of affecting nicotinic acetylcholinergic receptors (nAChRs), for example, as modulators of specific nicotinic receptor subtypes. The present invention also relates to methods for treating a wide variety of conditions and disorders, particularly those associated with dysfunction of the central and autonomic nervous systems.Nicotine has been proposed to have a number of pharmacological effects. See, for example, Pullan et al., N. Engl. J. Med. 330:811-815 (1994). Certain of those effects can be ...

CONFIGURABLE PROCESS CONTROL DEVICE WITH ELECTRONIC DISPLAY ASSEMBLY

A configurable process control device, which includes a field device, such as a valve position controller, that can be configured by a user to emulate any one of a plurality of different types of process control devices, is provided with an electronic display assembly. The electronic display assembly is operatively connected with a control circuit that is arranged to respond to the specific configuration of the field device to cause the electronic display assembly to display information relevant to the specific type of control device the field device has been configured to emulate. The information may include safety certification information specific to each of the different types of process control devices that the field device can be configured to emulate. 1. A configurable process control device for use in a plurality of use environments , wherein at least one of a pre-defined plurality of certifications must be displayed in conjunction with the configurable process control device depending on which of the use environments the configurable process control device is to be used in , the configurable process control device comprising:a field device;a first control circuit operatively coupled to the field device, the first control circuit arranged to control the field device and arranged to be reconfigured by a user to allow the field device to selectively emulate any of a plurality of different process control device types;an electronic display assembly, the electronic display assembly arranged to selectively display different information; anda second control circuit, the second control circuit operatively coupled to the electronic display assembly and the first control circuit, the second control circuit having access to a plurality of different certification information sets, each certification information set corresponding to a different one of the plurality of different process control device types;wherein the second control circuit causes the electronic display ...

PREPARATION AND THERAPEUTIC APPLICATIONS OF (2S, 3R)-N-2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)-3,5-DIFLUOROBENZAMIDE

The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS). 1. A method for treating one or more of age-associated memory impairment, mild cognitive impairment, pre-senile dementia, senile dementia, or Lewy body dementia, comprising administering to a patient in need thereof an effective amount of a compound (2S,3R)—N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide (Formula I) or a pharmaceutically acceptable salt thereof. The present invention is a continuation of U.S. patent application Ser. No. 12/740,970, filed Apr. 30, 2012, which is a §371 application of International Application No. PCT/US2010/021926, filed Jan. 25, 2010, which claims benefit to U.S. Provisional Application No. 61/147,260, filed Jan. 26, 2009, each of which is incorporated herein by reference in its entirety.The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS).The therapeutic potential of compounds that target neuronal nicotinic receptors (NNRs), also known as nicotinic acetylcholine receptors (nAChRs), has been the subject of several reviews (see, for example, Breining et al., 40: 3 (2005), Hogg and Bertrand, 3: 123 (2004), Suto and Zacharias, 8: 61 (2004), Dani et al., 14: 1837 (2004), Bencherif and Schmitt, 1: 349 (2002)). Among the kinds of indications for which NNR ...

PIEZOELECTRIC LOUDSPEAKER

The present invention discloses a piezoelectric loudspeaker. The piezoelectric loudspeaker comprises a sound producing plate, a resonant sound-box, a surround and a reflective sound-box. The sound producing plate comprises a piezoelectric ceramic element. The resonant sound-box includes a first opening comprising a first carrying part. The sound producing plate is disposed on the first carrying part. A cavity resonator is formed between the sound producing plate and the resonant sound-box. The surround is disposed between the first carrying part and the sound producing plate. The reflective sound-box includes a second opening and a reflective output opening. The second opening comprises a second carrying part. The resonant sound-box is disposed on the second carrying part. A reflective cavity body is formed between the resonant sound-box and the reflective sound-box, and the reflective cavity body is connected the reflective output opening. 1. A piezoelectric loudspeaker , comprising:a sound producing plate including at least one piezoelectric ceramic element being able to vibrate the sound producing plate;a resonant sound-box including a first opening comprising a first carrying part, the sound producing plate being disposed on the first carrying part, and a cavity resonator being formed between the sound producing plate and the resonant sound-box;a surround disposed between the first carrying part and the sound producing plate; anda reflective sound-box including a second opening and a reflective output opening, a second carrying part formed on a partial of an inner edge of the seconding opening, the resonant sound-box being disposed on the second carrying part, a reflective cavity body being formed between the resonant sound-box and the reflective sound-box, the reflective output opening being disposed on a side of the reflective sound-box, and the reflective cavity body being communicating with the reflective output opening.2. The piezoelectric loudspeaker of ...

Azetidinyloxy-, pyrrolidinyloxy-, and piperidinyloxy-substituted metanicotines as neuronal nicotinic acetylcholine receptor ligands

The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS).

EXO-S-MECAMYLAMINE FORMULATION AND USE IN TREATMENT

A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include but are not limited to substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), aiding smoking cessation, treating weight gain associated with smoking cessation, hypertension, hypertensive crisis, Tourette's Syndrome and other tremors, cancer (such as small cell lung cancer), atherogenic profile, neuropsychiatric disorders (such as bipolar disorder, depression, an anxiety disorder, schizophrenia, a seizure disorder, Parkinson's disease and attention deficit hyperactivity disorder), chronic fatigue syndrome, Crohn's disease, autonomic dysreflexia, and spasmogenic intestinal disorders. 1. An oral pharmaceutical composition for better symptom control and fewer side effects compared to racemic mecamylamine comprising:an effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof substantially free of exo-R-mecamylamine or a pharmaceutically acceptable salt thereof; andone or more pharmaceutically acceptable carriers.2. The oral pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is a unit dosage form.3. The oral pharmaceutical composition of claim 2 , wherein the unit dosage form is selected from the group consisting of a tablet claim 2 , capsule claim 2 , soft gelatin capsule claim 2 , hard gelatin capsule claim 2 , powder claim 2 , lozenge claim 2 , gum claim 2 , ...

TREATMENT WTH ALPHAT SELECTIVE LIGANDS

The present invention includes methods, uses, and selective alpha7 nAChR ligands for treating or preventing disease and disorders in which stimulation of neurogenesis is ameliorative; namely, wherein the recruitment of neurogenesis is therapeutic. 1 implanting stem cells or reactivating endogenous stem cells in a host in need of treatment', 'protecting said stem cells against host pathology;', 'stimulating migration and neuronal differentiation; and', 'promoting selective maturation to functional neurons., 'administering a selective α7 agonist, wherein said administration further comprises. A method for stem cell therapy comprising: The present invention includes methods, uses, and selective α7 nAChR ligands for treating or preventing disease and disorders in which stimulation of neurogenesis is ameliorative, namely, the recruitment of neurogenesis is therapeutic.Neurogenesis is the process by which new nerve cells are generated. In neurogenesis, there is active production of new neurons, astrocytes, glia and other neural lineages from undifferentiated neural progenitor or stem cells. Until recently, neurogenesis in mammals was believed to occur only during the embryonic and early post-natal periods and do not play a significant role in the adult nervous system. However, it is now accepted that neurogenesis occurs in at least two brain regions in adult mammals, the hippocampus and olfactory bulb (Ehninger and Kempermann, 331: 243-50 (2008)). In both regions new neurons arise from endogenous progenitor cells that are viable throughout adult life. Hippocampal neurogenesis is required for some types of hippocampal-dependent learning (Bruel-Jungerman et al., 18: 93-114 (2007)). Recently the relevance of hippocampal neurogenesis to the pathophysiology and treatment of mood disorders has received much attention. It is now known that all major pharmacological and non-pharmacological treatments for depression increase hippocampal neurogenesis (Malber et al., 20: 9104-9110 ( ...

1,4-DIAZABICYCLO[3.2.2]NONANES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS

The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including inflammatory diseases and diseases associated with dysfunction of the central nervous system (CNS). 3. A compound 5-(1 ,4-diazabicyclo[3.2.2]nonan-4-yl)-2-methyl-7H-isoxazolo[2 ,3-a]pyrimidin-7-one or a pharmaceutically acceptable salt thereof.4. A pharmaceutical composition comprising a compound of and one or more pharmaceutically acceptable carrier.5. The pharmaceutical composition of claim 4 , further comprising one or more additional active therapeutic agent.6. A pharmaceutical composition comprising a compound of and one or more pharmaceutically acceptable carrier.7. The pharmaceutical composition of claim 6 , further comprising one or more additional active therapeutic agent.8. A method of treating a α7 mediated disorder comprising administering a compound of .9. The method of claim 8 , wherein the α7 mediated disorder is age-associated memory impairment (AAMI) claim 8 , mild cognitive impairment (MCI) claim 8 , age-related cognitive decline (ARCD) claim 8 , pre-senile dementia claim 8 , early onset Alzheimer's disease claim 8 , senile dementia claim 8 , dementia of the Alzheimer's type claim 8 , Alzheimer's disease claim 8 , cognitive impairment no dementia (CIND) claim 8 , Lewy body dementia claim 8 , HIV-dementia claim 8 , AIDS dementia complex claim 8 , vascular dementia claim 8 , Down syndrome claim 8 , head trauma claim 8 , traumatic brain injury (TBI) claim 8 , dementia pugilistica claim 8 , Creutzfeld-Jacob Disease and prion diseases claim 8 , stroke claim 8 , central ischemia claim 8 , peripheral ischemia claim 8 , attention deficit disorder claim 8 , attention deficit hyperactivity disorder claim 8 , dyslexia claim 8 ...

Item Eligibility and/or Promotion Determination Application

In general, the present invention is directed to systems and methods of utilizing an application operating on a mobile device to determine any applicable offers or eligibility and rank such offers and eligibility for user selection. More specifically, a process may be conducted by a processor in communication with a mobile device and data stores including user data, retailer data, and/or product and service data, the process including comparing identification information associated with a product or service received from the mobile device with data in the data stores; determining the product or service and identifying any associated promotional offers or plan eligibility associated with the product or service, the user, and/or the retailer; ranking any promotional offers or plan eligibility based at least in part on size of promotion; transmitting to the mobile device an identifier of applicable promotional offers or plan eligibility. 1. A system , comprising:a processor; user data, including memberships, groups, plans, and/or entitlements associated with a user;', products and services offered by a retailer;', 'any promotional offers offered by the retailer;, 'retailer data, including, 'product and service data, including identification information of each product and service, and any promotional offers or plan eligibility associated with the product or service;, 'one or more data stores, the one or more data stores storing data comprisingwherein the processor is in selective communication with one or more retailers, manufacturers, membership plans, insurance providers, and/or entitlement providers to populate and update the one or more data stores;wherein the processor is in selective communication with a mobile device of the user; comparing first media data comprising identification information associated with a product or service received from the mobile device with product and service data stored in the one or more data stores;', 'based at least in part on the ...

QUICK DISCONNECT CONNECTOR ASSEMBLY

A quick-disconnect connector assembly includes a housing having a bore that extends up to but not through a first end of the housing. The connector assembly also includes a proximity switch disposed within the bore, and the proximity switch includes a switch body, a first contact member, and a second contact member. A portion of each of the first and second contact members extends from the switch body towards a second end of the housing. In a first switch position, a contact of a displaceable switching assembly is in contact with the first contact member, and in a second switch position, the contact is in contact with the second contact member. The connector assembly also includes an external connection assembly including a first pin that is electrically coupled to the first contact member and a second pin that is electrically coupled to the second contact member. 1. A quick-disconnect connector assembly comprising:a housing that extends along a longitudinal axis from a first end to a longitudinally-opposite second end, the housing including one or more interior surfaces that cooperate to define a bore that extends from the second end to a point adjacent to the first end such that the bore does not extend through the first end of the housing, wherein the bore includes a first bore portion; a switch body extending along a body longitudinal axis, the switch body having a first end disposed adjacent to the first end of the housing and a longitudinally-opposite second end; and', 'a first contact member and a second contact member, each of the first and second contact members having a first end and a longitudinally-opposite second end, the second end being disposed within the switch body and the first end being disposed external to the switch body, wherein a portion of each of the first and second contact members extends from the second end of the switch body towards the second end of the housing,', 'wherein in a first switch position, a contact of a displaceable ...

Nicotinic receptor non-competitive antagonists

The present invention relates to compounds that modulate nicotinic receptors as non-competitive antagonists, methods for their synthesis, methods for their use, and their pharmaceutical compositions.

Adjustable orthotic foot brace and method for adjusting a foot brace

The orthotic foot brace for a person wearing a footwear generally has: a lower leg holder securable to a lower leg of the person for use, a lower leg strut connected to the lower leg holder and extending downwardly towards the footwear during use; a foot strut structurally connected to the lower leg strut and having at least one side portion, each side portion extending forwardly along a respective side of the footwear and extending outwardly along a respective side of the footwear; an instep strut provided in the form of an extension of the foot strut along a long axis of the footwear, the instep strut having a distal portion securable to the footwear, and at least a proximal portion being slidably connected to the foot strut in a manner to allow adjusting the extension distance of the distal portion to a selected position.

Nicotinic receptor non-competitive antagonists

The present invention relates to compounds that modulate nicotinic receptors as non-competitive antagonists, methods for their synthesis, methods for use, and their pharmaceutical compositions.

TRACEABLE METALLIC PRODUCTS AND METALLIC SUPPORT FOR NANOSTORAGE

The invention relates to traceable metallic products, methods of uses and methods of making same. The metallic products may be made traceable for integrity purposes, identification purposes, counterfeit avoidance and the like. The invention also relates to metallic supports for nanostorage of various compounds and samples. 1. A traceable metallic product , wherein said metallic product comprises a porous surface layer formed by anodization , and wherein said porous surface layer comprises at least one traceable biological compound.2. (canceled)3. The traceable metallic product of claim 1 , wherein said at least one traceable biological compound is selected from the group consisting of nucleic acids claim 1 , peptidic molecules claim 1 , lipids claim 1 , mono and polysaccharides claim 1 , hormones claim 1 , vitamins claim 1 , and derivatives thereof.4. (canceled)5. The traceable metallic product of claim 1 , wherein said at least one traceable biological compound is carried in nanopores of the porous surface layer claim 1 , and wherein said at least one traceable compound is recoverable from said porous surface layer for detection claim 1 , identification and/or utilization purposes.6. (canceled)7. The traceable metallic product of claim 1 , wherein said traceable metallic product consists of a metallic support for nanostorage of compound and samples.8. The traceable metallic product of claim 1 , wherein said porous surface layer is sealed.9. The traceable metallic product of claim 1 , wherein said porous surface layer further comprises an electrodeposit of at least one metal selected from the group consisting of silver claim 1 , gold claim 1 , copper claim 1 , nickel claim 1 , zinc claim 1 , tin claim 1 , cadmium claim 1 , palladium and platinum.10. The traceable metallic product of claim 1 , wherein said traceable metallic product consists of a traceable piece of aluminum comprising a porous surface layer formed by anodization claim 1 , and wherein said porous ...

VALVE SIGNATURE DIAGNOSIS AND LEAK TEST DEVICE

A valve signature diagnosis and leak testing device includes a spool valve operatively connected to a pilot valve, the pilot valve being configured to position the spool valve to one of an open position and a closed position. A blocker valve is fluidly connected to a control fluid outlet of the spool valve. An electrical module is operatively connected to the pilot valve, a supply of control fluid, and the blocker valve, the electrical module being capable of sending pulsed electrical signals to the pilot valve and the blocker valve to selectively position the spool valve and the blocker valve to an open or closed position.

Compositions and Methods for siRNA Inhibition of Angiogenesis

System for cleaning and sanitizing

The present invention provides a system ( 10 ) for cleaning and sanitizing surfaces that incorporates a high pressure fluid supply ( 52 ) and a low pressure fluid supply ( 42 ), often carrying an ozonated fluid, and alternates directed streams of the two fluids for application to contaminated surfaces through a single applicator ( 70, 100 ).

Compounds

COMPOSITION

Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain

Disclosed is a cysteine engineered antibody compriDisclosed is a cysteine engineered antibody comprising a free cysteine amino acid having a thiol reasing a free cysteine amino acid having a thiol reactivity value in the range of 0.6 to 1.0; and a sectivity value in the range of 0.6 to 1.0; and a sequence in the heavy chain selected from SEQ ID NOSquence in the heavy chain selected from SEQ ID NOS: 11, 12, 13, and 15: LVTVCSASTKGPS SEQ ID NO:11 : 11, 12, 13, and 15: LVTVCSASTKGPS SEQ ID NO:11 LVTVSCASTKGPS SEQ ID NO:12 LVTVSSCSTKGPS SEQ ID LVTVSCASTKGPS SEQ ID NO:12 LVTVSSCSTKGPS SEQ ID NO:13 HTFPCVLQSSGLYS SEQIDNO:15 where the cysteiNO:13 HTFPCVLQSSGLYS SEQIDNO:15 where the cysteine in SEQ ID NOS: 11, 12, 13, and 15 is the free cne in SEQ ID NOS: 11, 12, 13, and 15 is the free cysteine amino acid. Also disclosed are antibody-drysteine amino acid. Also disclosed are antibody-drug conjugate compounds with the cysteine engineereug conjugate compounds with the cysteine engineered antibody described above and a drug moiety selecd antibody described above and a drug moiety selected from a maytansinoid, an auristatin, a dolastatted from a maytansinoid, an auristatin, a dolastatin, and a calicheamicin. in, and a calicheamicin.

Solenoid actuated butterfly valve

A butterfly valve (100) and a valve system using the butterfly valve are disclosed. The butterfly valve includes a valve body (102) and a valve disk (112) disposed in the body such that the valve disk may be rotated between at least a first position and a second position using a linear actuator. The actuator may be a linear solenoid coupled to the valve disk spaced a distance from the axis of rotation of the valve disk.

Methods and compositions relating to chimeric nicotinic receptor subunits

Multivalent antibodies and uses therefor. Multivalent antibodies and uses thereof.

Energy activated printing process

给出了反应性油墨和在基材上使用反应性且热激活的油墨产生图像的方法。在基材上印刷图像，而不使该油墨中的反应试剂反应。随后，使该反应试剂反应而将图像显著持久且牢固地固定到基材上。还将印刷的升华或类似热激活的染料印刷在该基材上。该升华或类似热激活的染料被激活，并且对施加到基材上的聚合物具有亲合性。

Fused benzazepines as neuronal nicotinic acetylcholine receptor ligands

Method and apparatus for making insulating translucent panel assemblies

A method of making an insulating translucent panel assembly (10) such as a window or door lite is provided. In the method, a spacer (16) between two translucent panels (12) of glass or plastic includes a thermo- responsive sealing material (22). When heat and compression are applied to the spacer (16), the thermo-responsive sealing material (22) softens and fully seals the spacer (16) to the two translucent panels (12). A spacer (16) designed to be used in this method is also provided.

Patent DE4028660C2

Liquid flourescent dye concentrate for flow cytometry evaluation of virus-size particles and related products and methods

A kit, and method for flow cytometry include a liquid dye concentrate for fluorescent staining of virus-size particles with a plurality of fluorogenic dyes in a liquid medium. The liquid dye concentrate includes a plurality of fluorogenic dyes and one or both of (i) the liquid medium comprising a liquid mixture including water and liquid phase organic material and (ii) disaccharide dissolved in the liquid medium.

Arylvinylazacycloalkane compounds and methods of preparation and use thereof

Methods and compositions for the treatment of central nervous system disorders

Disclosed is a pharmaceutical composition for treatment or prophylaxis of a central nervous system disorder for administration to a subject suffering from the disorder, comprising a compound of formula I that stimulates a nicotine receptor; either or both of at least one inhibitor of the AT2 receptor or at least one inhibitor of a substance that stimulates the AT2 receptor, and a pharmaceutically acceptable carrier.

Treatment of cognitive dysfunction in schizophrenia

The present invention relates to (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide or a pharmaceutically acceptable salt thereof, pharmaceutical compositions, and methods for treating schizophrenia.

Hydroxybenzoate salts of metanicotine compounds

Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof compositions that are hydroxybenzoate salts of E-metanicotine-type compounds. The formation of hydroxybenzoate salts of the E-metanicotine compounds is also useful in purifying the E-metanicotine compounds, as the hydroxybenzoate salts tend to crystallize out, leaving impurities such as Z-metanicotine compounds, and compounds where the double bond has migrated, in solution. If desired, the hydroxybenzoate salts can be converted to either the free base (the E-metanicotine) or to another pharmaceutically acceptable salt form.

Polymorph forms of (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin) yl]-4-penten-2-amine p-hydroxybenzoate for the treatment of central nervous system disorders

Smeša polimorfa koja sadrži:a. kristalni polimorf A (2S)-(4E)-N-metil-5-[3-(5-izopropoksipiridin)il]-4-penten-2-amin p-hidroksibenzoata, koji ispoljava obrazac rendgenske difrakcije praha sa karakterističnim maksimumima izraženim u stepenima (2-9) od oko 7.6 i 15.2 i 19.7, ib. kristalni polimorf B (2S)-(4E)-N-metil-5-[3-(5-izopropoksipiridin)il]-4-penten-2-amin p-hidroksibenzoata, koji ispoljava obrazac rendgenske difrakcije praha sa karakterističnim maksimumima izraženim u stepenima (2-9) od oko 8.0, 9.6 i 16.1.Prijava sadrži još 14 patentnih zahteva. A mixture of polymorphs containing: a. crystalline polymorph A (2S) - (4E) -N-methyl-5- [3- (5-isopropoxypyridinyl) yl] -4-penten-2-amine p-hydroxybenzoate, which exhibits an X-ray powder diffraction pattern with characteristic maxima expressed in degrees (2-9) of about 7.6 and 15.2 and 19.7, ib. crystalline polymorph B (2S) - (4E) -N-methyl-5- [3- (5-isopropoxypyridinyl) yl] -4-penten-2-amine p-hydroxybenzoate, which exhibits an X-ray powder diffraction pattern with characteristic maxima expressed in degrees (2-9) of about 8.0, 9.6 and 16.1. The application contains 14 more claims.

treatment of cognitive dysfunctions in schizophrenia

tratamento de disfunções cognitivas em esquizofrenia a presente invenção refere-se a (2s, 3r)-n-(2 - ((3-piridinil) metil)-1-azabiciclo [2.2.2] oct-3-il) benzofurano-2-carboxamida ou um sal farmaceuticamente aceitável do mesmo, composições farmacêuticas, e métodos para o tratamento da esquizofrenia. Treatment of Cognitive Disorders in Schizophrenia The present invention relates to (2s, 3r) -n- (2 - ((3-pyridinyl) methyl) -1-azabicyclo [2.2.2] oct-3-yl) benzofuran-2 -carboxamide or a pharmaceutically acceptable salt thereof, pharmaceutical compositions, and methods for treating schizophrenia.

Imaging of nicotinic acetylcholine receptor subtypes

Compounds useful as probes for determining the relative number and/or function of specific receptor subtypes. Of particular interest are nicotinic agonists and antagonists (e.g., metanicotine-type compounds and azaadamantane-type compounds) that are selective to certain nicotinic receptor subtypes. Those compounds are labeled with a radioactive isotopic moiety such as ?11C, 18F, 76Br, 123I or 125¿I. Central nervous system disorders are diagnosed by administering to a patient a detectably labeled compound, and detecting the binding of that compound to selected nicotinic receptor subtypes (e.g., alpha 7 and/or alpha 4 beta 2 receptor subtypes). The compounds that have been administered are detected using methods such as position emission topography (PET) and single-photon emission computed tomography (SPECT). The present invention is useful in the diagnosis of a wide variety of CNS diseases and disorders, including Alzheimer's disease, Parkinson's disease and schizophrenia.

Method of constructing and executing a process

Disclosed is a method of constructing and executing a process. A conventional process is minutely divided into minimum unit subprocesses, and the minutely divided subprocesses are classified into a decision subprocesses and a routine subprocess by whether they require decision-making. Any subprocess which is executable using the setup condition in a specific decision subprocess is classified into the routine subprocess in such a manner that the classified routine subprocess follows on the specific decision subprocess. One or a series of decision subprocesses are combined with one or a series of routine subprocesses which are executable on the condition of the completion of the decision subprocesses to form one unit process, and a job-support computer program is created to allow the plurality of subprocesses included in the one unit process to be successively executed. A plurality of subprocesses which are executable in accordance with common input data are detected from the minutely divided minimum unit subprocesses, and a job flow is constructed to allow the respective jobs in the plurality of subprocesses to be simultaneously initiated and executed in parallel. The present invention can drastically reduce the lead-time of a process while facilitating execution of the entire process with high efficiency.

Enclosed proximity switch assembly

An enclosed proximity switch assembly includes a top enclosure and a bottom enclosure that are coupled to form an interior volume. A shaft protrusion upwardly extends from a top surface of the top enclosure, and an interior bore portion having an enclosed volume is defined within the shaft protrusion to form a portion of the interior volume. A first end of a vertical shaft is rotatably disposed within the interior bore portion such that the shaft rotates relative to the top and bottom enclosures. A samarium cobalt target magnet is coupled to the shaft, and the target magnet interacts with a samarium cobalt driver magnet within a proximity switch when the target magnet is rotated within a predetermined distance of a top portion of the proximity switch. The interaction causes a switch to move from a first state to a second state, or vice versa.

PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF CNS DISEASES

New process for the preparation of aryl substituted olefinic amines

Pharmaceutical compositions and methods for their use

Compounds derived from 3,6-diazabicyclo [3.1.1] heptanes, as ligands for neuronal nicotinic acetylcholine receptors; pharmaceutical composition; and its use for the treatment or prevention of presenile dementia, Alzheimer's, schizophrenia, acute or chronic pain, among other diseases.

Nicotinic receptor non-competitive modulators

Salt forms of (2S)-(4E)-N-Methyl-5-[(5-Isopropoxy)pyridin-3-yl]-4-penten-2-amine

Citric acid and D-aspartic acid salts of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine, and methods for their preparation, pharmaceutical compositions comprising said salts, and use, are disclosed. The salts can be administered to patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, to treat and/or prevent such disorders.

Polymorph forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin) yl]-4-penten-2-amine p-hydroxybenzoate for the treatment of central nervous system disorders

Component of printed circuit boards

A component (10) for use in manufacturing articles, such as printed circuit boards, comprising a laminate constructed of a sheet of copper foil (20) that, in a finished circuit board, constitutes a functional element, and a sheet of carbon steel (14) having a layer of an inert metal (16) thereon, the sheet of carbon steel (14) constituting a discardable element. One surface (22) of the copper sheet (20) and the surface (18) of the inert metal layer (16) on the carbon steel sheet (14) are essentially uncontaminated and engageable with each other at interfaces. The copper sheet (20) is attached to the inner metal layer (16) of the carbon steel (14) at their borders and defines substantially uncontaminated central zones inwardly of the edges of the sheets that are unjoined at the interfaces.

Arylvinylazacycloalkane Compounds and Methods of Preparation and Use Thereof

Novel vinylazacycloalkane compounds of Formula (I) are disclosed. The compounds are ligands of various nAChRs. The compounds and their pharmaceutically acceptable salts can be used to prepare pharmaceutical compositions and/or medicaments intended to prevent or treat disorders associated with dysfunction of nAChRs, especially within the central nervous system or the gastrointestinal system. Examples of types of disorders that can be treated include neurodegenerative disorders, including central nervous system disorders such as Alzheimer's disease, cognitive disorders, motor disorders such as Parkinson's disease, drug addiction, behavioral disorders and inflammatory disorders within the gastrointestinal system. The compounds can also serve as analgesics in the treatment of acute, chronic or recurrent pain.

(2s,3r)-n-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms, and methods of use thereof

Methods and compositions relating to chimeric nicotinic receptor subunits

Azatricyclic Compounds

Nicotinic receptor non-competitive antagonists

The present invention relates to compounds that modulate nicotinic receptors as non-competitive antagonists, methods for their synthesis, methods for use, and their pharmaceutical compositions.

Data generating device, data generating method and data generating program

Nicotinic acetylcholine receptorsub-type selective amides of diazabicycloalkanes

AMIDI DIAZABICIKLOALKANA SELEKTIVNI NA PODVRSTU NIKOTINSKIH ACETILHOLINSKIH RECEPTORA. Jedinjenje N-(5-hlorofuran-2-ilkarbonil)-3,7-diazabiciklo[3.3.0]oktan, ili neka njegova farmaceutski prihvatljiva so.Prijava sadrži još 8 patentnih zahteva. DIAZABICYCLOALKANE AMIDES SELECTIVE ON THE SUBSYPE OF NICOTINE ACETYLCHOLINE RECEPTORS. The compound N- (5-chlorofuran-2-ylcarbonyl) -3,7-diazabicyclo [3.3.0] octane, or a pharmaceutically acceptable salt thereof. The application comprises 8 further claims.

(2s,3r) - n - (2 - ((3 - pyridinyl) methyl) - 1 - azabicyclo [2.2.2] oct - 3 - yl) benzofuran - 2 - carboxamide, novel salt forms, and methods of use thereof

3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof

The present invention relates to pharmaceutical compositions incorporating compounds capable of affecting nicotinic acetylcholinergic receptors (nAChRs), for example, as modulators of specific nicotinic receptor subtypes (specifically, the α 7 nAChR subtype). The present invention also relates to methods for treating a wide variety of conditions and disorders, particularly those associated with dysfunction of the central and autonomic nervous systems.

Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloal kanes

The present invention relates to compounds of the following formula (I) that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS).

Compositions containing diacyltartaric salts of (E)-metanicotine

Process for the preparation of aryl substituted olefinic amines

An improved process for the preparation of aryl substituted olefinic amines such as (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine and (2S)-(4E)-N-methyl-5-[3-(5-methoxypyridin)yl]-4-penten-2-amine and new intermediates used in said process.

Systems and methods for providing, reloading, and redeeming stored value cards used in transit applications

The invention is directed to systems and methods of conducting transactions associated with a transit card. A method of conducting transactions may be conducted between a processor and a transit processor. Steps may include receiving a redemption request and determining if it is a pre-authorization request or a redemption; if the redemption request is a pre-authorization request, determining if the account is authorized for a particular transit type. If the account is authorized, communicating approval to the transit processor. If the account is not authorized communicating denial. If the redemption request is a redemption: determining if account value is sufficient to pay the redemption amount; if not, denying and if so approving the transaction and deducting the amount, and determining if the account value is below a pre-determined threshold for a particular transit types, and if so, updating the status of the account at a data store.

Alpha7 nachr agonists for treating or preventing metabolic disorders

The present invention includes methods, uses, and selective a7 nAChR agonist compounds for treating or preventing metabolic disorders.

(2s,3r)-n-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms, and methods of use thereof

The present invention relates to (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms thereof, methods for its preparation, novel intermediates, and methods for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central and autonomic nervous systems.

Methods for preventing the development of retinopathy by the oral administration of nnr ligands

Method and compositions for delaying the onset or progression of retinopathy, including administering at least one neuronal nicotinic ligand are disclosed.

Nicotinic receptor non-competitive antagonists

The present invention relates to compounds that modulate nicotinic receptors as non-competitive antagonists, methods for their synthesis, methods for use, and their pharmaceutical compositions.

Pharmaceutical compositions and methods for effecting dopamine release

Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia), are treated by administering a 1-aza-2-(3-pyridyl)bicyclo[2.2.1]heptane, a 1-aza-2-(3-pyridyl)bicyclo[2.2.2]octane, a 1-aza-2-(3-pyridyl)bicyclo[3.2.1]octane, a 1-aza-2-(3-pyridyl)bicyclo[3.2.2]nonane, a 1-aza-7-(3-pyridyl) bicyclo[2.2.1]heptane, a 1-aza-3-(3-pyridyl)bicyclo[3.2.2]nonane, or a 1-aza-7-(3-pyridyl)bicyclo[3.2.2]nonane. The compounds can exist as individual stereoisomers, racemic mixtures, diastereomers and the like.

Combination therapy for the management hypertension

The present invention includes a combination comprising: a) mecamylamine; and b) an ACE inhibitor, an AT2 receptor inhibitor, a renin inhibitor, or a combination thereof.

Sub-type selective amides of diazabicycloalkanes

Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are amide compounds which can be prepared from certain heteroaryl carboxylic acids and certain diazabicycloalkanes. The compounds exhibit selectivity for, and bind with high affinity to, neuronal nicotinic receptors of the α4β2 subtype in the central nervous system (CNS). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly CNS disorders. The compounds can: (i) alter the number of nicotinic cholinergic receptors of the brain of the patient, (ii) exhibit neuroprotective effects, and (iii) when employed in effective amounts, not result in appreciable adverse side effects (e.g. side effects such as significant increases in blood pressure and heart rate, significant negative effects upon the gastrointestinal tract, and significant effects upon skeletal muscle).

Dual/variable gain oil pump control valve

A solenoid fluid control valve is disclosed for controlling a variable displacement pump. The solenoid fluid control valve comprises a fixed solenoid component (702), a movable armature component (710), a fixed nozzle body (722), a movable spool (720) within the fixed nozzle body, and a valve member (714). The valve member regulates fluid pressure in a first (746, 748) and second feedback chamber. Fluid in the second feedback chamber establishes a second feedback pressure that acts on the movable spool with a motive feedback force in a first axial direction. The movable spool moves in the first axial direction in response to the motive feedback force.

COMPOSITE OF 1-AZABICICLO [2.2.2] OCTANO AND USES FOR THE TREATMENT OF SCHIZOPHRENIA

La presente se relaciona con (2S,3R)-N-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida o una sal correspondiente farmacéuticamente aceptable, composiciones farmacéuticas y métodos para el tratamiento de la esquizofrenia. This is related to (2S, 3R) -N- (2 - ((3-pyridinyl) methyl) -1-azabicyclo [2.2.2] oct-3-yl) benzofuran-2-carboxamide or a corresponding pharmaceutically acceptable salt , pharmaceutical compositions and methods for the treatment of schizophrenia.

Arylvinylazacycloalkane compounds

Nicotinic receptor non-competitive antagonists

The present invention relates to compounds that modulate nicotinic receptors as non-competitive antagonists, methods for their synthesis, methods for use, and their pharmaceutical compositions.

Pharmaceutical compositions and methods for use

Pharmaceutical compositions aryl substituted amine compounds, and in particular, 3-aminophenyl amine compounds are provided. Representative compounds are (E)-4-(3-aminophenyl)-3-buten-1-amine, (E)-N-methyl-4-(3-aminophenyl)-3-buten-1-amine and (E)-N-methyl-5-(3-aminophenyl)-4-penten-2-amine.

A process for the preparation of tert-butyl (r)-3-vinylpyrrolidine-1- carboxylate and intermediates therefor

Polymorph forms of (2S) - (4E) -N-methyl-5- (3-isopropoxypyridin) yl] -4-penten-2-amine for the treatment of central nervous system disorders

Polymorph forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4- penten-2-amine p-hydroxybenzoate, and methods for their preparation, pharmaceutical composition containing said polymorph(s) and use, are disclosed. The polymorphs can be administered to patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, to treat and/or prevent such disorders.

(2s,3r)-n-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms, and methods of use thereof

The present invention relates to (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms thereof, methods for its preparation, novel intermediates, and methods for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central and autonomic nervous systems.

N-(heteroarylcarbonyl) derivatives of 3,7-diazabicyclononane/-octane and pharmaceutical compositions comprising them for treating cns disorders

Nicotinic receptor non-competitive antagonists

The present invention relates to compounds that modulate nicotinic receptors as non-competitive antagonists, methods for their synthesis, methods for their use, and their pharmaceutical compositions.

A kind of industrial waste gas dust treatment device

本实用新型公开了一种工业废气粉尘处理装置，包括壳体，所述壳体内壁的顶部对称设置有第一支撑柱，两个第一支撑柱的底部通过第一吸尘管固定连接，所述壳体顶部的中点处固定连接有吸尘风机，所述吸尘风机的底部从上至下依次贯穿壳体和第一吸尘管且延伸至第一吸尘管的内部。本实用新型通过壳体、第一吸尘管、吸尘风机、过滤水箱、第二吸尘管、第三吸尘管、冲刷水箱、第一水管、冲刷喷头、旋转电机、旋转转轴、滚筒、海绵吸附棒、活性炭吸附层、过滤板、出水口、循环水池、循环水泵、第三水管和第四水管相互配合，起到了防逸散的效果，能够有效去除废气中的粉尘，保护了工作人员的身体健康，提高了工作人员的工作积极性。

ARYLVINYLACACYCLOKALANIA AND METHODS OF PREPARATION AND USE

Αποκαλύπτονται νέα βινυλαζακυκλοαλκάνια Τύπου (Ι). Οι ενώσεις είναι προσδέματα διαφόρων nAChR. Οι ενώσεις και τα φαρμακευτικά αποδεκτά άλατά τους μπορούν να χρησιμοποιηθούν για την παρασκευή φαρμακευτικών συνθέσεων και/ή φαρμάκων προοριζόμενων για την πρόληψη ή την αγωγή διαταραχών σχετιζόμενων με δυσλειτουργία των nAChR, ιδιαίτερα εντός του κεντρικού νευρικού συστήματος ή του γαστρεντερικού συστήματος. Παράδειγμα τύπων διαταραχών οι οποίες μπορούν να αντιμετωπισθούν περιλαμβάνουν νευροεκφυλιστικές διαταραχές, περιλαμβανομένων διαταραχών του κεντρικού νευρικού συστήματος όπως η νόσος του Alzheimer, νοητικές διαταραχές, κινητικές διαταραχές όπως η νόσος του Parkinson, τον εθισμό σε φάρμακα, διαταραχές της συμπεριφοράς και φλεγμονώδεις διαταραχές εντός του γαστρεντερικού συστήματος. Οι ενώσεις μπορούν επίσης να χρησιμεύουν ως αναλγητικά στην αγωγή του οξέως, χρόνιου ή υποτροπιάζοντος άλγους. New Type (I) vinylazacycloalkanes are disclosed. The compounds are ligands of various nAChRs. The compounds and their pharmaceutically acceptable salts may be used for the preparation of pharmaceutical compositions and / or drugs intended to prevent or treat nAChR-related disorders, particularly within the central nervous system or gastrointestinal system. Examples of types of disorders that can be treated include neurodegenerative disorders, including central nervous system disorders such as Alzheimer's disease, mental disorders, motor disorders such as Parkinson's disease, drug addiction, behavioral disorders and inflammatory disorders. . The compounds may also serve as analgesics in the treatment of acute, chronic or recurrent pain.

Alpha 7 nicotinic agonists and antipsychotics

本发明涉及α7烟碱激动剂和抗精神病药的协同组合。